DAVID STENEHJEM

Adjunct Associate Professor

Pharmacotherapy

  • Adjunct Associate Professor
    Pharmacotherapy

RESEARCH INTERESTS

My research expertise is phase I clinical trials in oncology and oncology-related outcomes research to inform personalized health care decision-making. My research focuses on using electronic health record data supporting comparative-effectiveness research and health technology assessment to understand the value of personalized medicine and pharmacotherapy.

GRANTS

  • EXTERNAL GRANT OR CONTRACT
    REAL-WORLD TREATMENT PATTERNS AND CLINICAL OUTCOMES IN METASTATIC PROSTATE CANCER BY HORMONE SENSITIVITY AND HOMOLOGOUS RECOMBINATION REPAIR GENE MUTATIONS
    9 Jul 2025 - 31 Dec 2026
  • EXTERNAL GRANT OR CONTRACT
    REAL-WORLD MANAGEMENT AND TREATMENT OF DESMOID TUMORS AMONG PATIENTS WITH FAMILIAL ADENOMATOUS POLYPOSIS
    29 May 2025 - 31 Dec 2027
  • EXTERNAL GRANT OR CONTRACT
    TREATMENT PATTERNS AND OUTCOMES OF PATIENTS WITH METASTATIC PANCREATIC ADENOCARCINOMA
    29 Jan 2025 - 31 Dec 2026
  • EXTERNAL GRANT OR CONTRACT
    IDENTIFICATION AND CHARACTERIZATION OF PATIENTS WITH DESMOID TUMOR AND THE ASSOCIATED EPIDEMIOLOGY IN THE US
    SPRINGWORKS THERAPEUTICS17 May 2023 - 30 Jun 2026
    SPRINGWORKS THERAPEUTICS
  • EXTERNAL GRANT OR CONTRACT
    IDENTIFYING TREATMENT AND TESTING DISPARITIES IN METASTATIC BREAST CANCER TO IMPROVE TREATMENT PATHWAYS AND OUTCOMES.
    ASTRAZENECA28 Nov 2022 - 30 Jun 2026
    ASTRAZENECA
  • EXTERNAL GRANT OR CONTRACT
    AZ MESO
    ASTRAZENECA1 Jan 2015 - 31 Dec 2016
    ASTRAZENECA
  • EXTERNAL GRANT OR CONTRACT
    MYRIAD GENETIC COUNSELING
    MYRIAD GENETICS INC1 Jan 2015 - 31 Dec 2017
    MYRIAD GENETICS INC
  • EXTERNAL GRANT OR CONTRACT
    CML EXPANSION
    NOVARTIS PHARMACEUTICALS CORP1 Jan 2014 - 31 Dec 2014
    NOVARTIS PHARMACEUTICALS CORP
  • EXTERNAL GRANT OR CONTRACT
    OVARIAN CANCER WILDTYPE V BRCA
    ASTRAZENECA11 Nov 2013 - 31 Dec 2015
    ASTRAZENECA